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Abstract
AWorld Health Organization expert meeting on Ebola vaccines proposed
urgent safety and efficacy studies in response to the outbreak in West
Africa. One approach to communicable disease control is ring vaccination
of individuals at high risk of infection due to their social or geographical
connection to a known case. This paper describes the protocol for a
novel cluster randomised controlled trial design which uses ring
vaccination.
In the Ebola ça suffit ring vaccination trial, rings are randomised 1:1 to
(a) immediate vaccination of eligible adults with single dose vaccination
or (b) vaccination delayed by 21 days. Vaccine efficacy against disease
is assessed in participants over equivalent periods from the day of
randomisation. Secondary objectives include vaccine effectiveness at
the level of the ring, and incidence of serious adverse events.
Ring vaccination trials are adaptive, can be run until disease elimination,
allow interim analysis, and can go dormant during inter-epidemic periods.
Evaluating vaccine efficacy during outbreaks can be challenging
due to the timescales involved, ethical concerns around research
methods, and field operational challenges such as cold chain
management and effective communication with those affected.
Furthermore, to have adequate statistical power to detect a
vaccine effect, a sufficient number of events must be observed.
These challenges have again come to international attention due
to the devastating epidemic of Ebola virus disease (EVD) in
West Africa,1 where weak infrastructure for health and
development exacerbate the difficulties inherent in
communicable disease control and related interventional
research.
An approach to increasing vaccine study power is to recruit
those at highest risk of infection. A trial might thus recruit
individuals who are socially or geographically connected to a
case and therefore at increased risk of infection and developing
disease within a few weeks. When implemented as a targeted
programmatic public health measure, such an approach is
described as “ring vaccination.”
A surveillance-containment strategy using ring vaccination was
central to smallpox eradication in the 1970s. This contributed
to the interruption of transmission in Africa, South America,
and Asia.2 Ring vaccination with an efficacious vaccine might
similarly help to control other communicable diseases by
creating a buffer of immune people around each new case,
thereby preventing further spread of the infection. Simulation
studies suggest ring vaccination can contain outbreaks of
infectious diseases with relatively low reproduction numbers
(R0),3 such as EVD, for which R0 has been estimated at between
1 and 3.4 5 Some studies note that effective contact tracing, case
isolation, and quarantine or monitoring of cases can have an
effect equivalent to ring vaccination.3 6 A ring vaccination trial
therefore tests both the vaccine and the approach.
In this paper, we describe the design considerations behind the
protocol for a ring vaccination trial, a novel cluster randomised
controlled trial to evaluate vaccines against EVD in Guinea,
West Africa.
The Ebola ça suffit randomised ring
vaccination trial
In the Ebola ça suffit (“Ebola, that’s enough”) ring vaccination
trial, a person newly diagnosed with EVD becomes the index
case around whom an epidemiologically defined ring is formed.
This ring is then randomised to either immediate vaccination
(intervention) or delayed vaccination (control) in a 1:1 ratio on
an open label basis. The incidence of disease is compared
between the two arms over equivalent time periods measured
from the time of randomisation of each ring. Comparing the
hazard ratio in those enrolled in the study allows estimation of
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Key points
• Evaluating the efficacy of novel vaccines and therapeutics in epidemics is challenging, with situations evolving rapidly and ethical
concerns about research during public health emergencies
• Ring vaccination around cases was used successfully in the smallpox eradication programme
• A novel cluster randomised control trial of immediate versus 21 day delayed ring vaccination against Ebola is underway in Guinea
• A ring vaccination trial tracks the epidemic, recruiting individuals at raised risk of infection due to their connection to a case: this design
may both contribute to transmission interruption and have a higher power to detect vaccine efficacy than other study designs
vaccine efficacy, while overall vaccine effectiveness can be
estimated by comparing incidence across all members of the
rings, including those not eligible for vaccination in the study.
Intervention and control
The trial tests the recombinant vesicular stomatitis virus Ebola
vaccine (rVSV-ZEBOV), which was developed by the Public
Health Agency of Canada, and licensed to NewLink Genetics
and Merck. rVSV-ZEBOV was selected based on its safety
profile, induction of potentially protective immune responses,
including neutralising antibodies, and availability of vaccine
doses.
In a ring vaccination trial, the control arm could be a placebo
or a vaccine against a disease not under study. This was deemed
unacceptable in Guinea because of national and international
concerns about leaving vulnerable individuals unprotected
against EVDwhen a potentially effective vaccine was available.7
An assessment of the epidemiology of EVD inGuinea was done,
which suggested that a 21 day delay, the incubation period in
which 95% of EVD cases arise,5 for the control arm could be
sufficient to determine efficacy, while meeting the requirement
to minimise study participants’ time without vaccination. In
Guinea the trial is open label, but in settings with fewer
operational challenges a ring vaccination trial of immediate
versus delayed vaccination could include blinding of allocation
by using additional visits to each study arm for the
administration and follow-up of a placebo or non-study vaccine.
In the Ebola ça suffit ring vaccination trial, both the immediate
and delayed vaccination arms receive equivalent infection
prevention and control advice at enrolment. This includes
informing study participants that the vaccine may not offer
protection, so they should not take risks with Ebola exposure,
and that the vaccine may not prevent Ebola in people already
infected.
Design and implementation
The recruitment of ring vaccination trial study participants is
driven by the detection of new cases. After notification of a
laboratory confirmed EVD case in Basse-Guinea, the designated
trial area, a contact list is drawn up by study field teams using
the World Health Organization (WHO) contact tracing record.8
The newly diagnosed EVD case becomes the index case around
which an epidemiologically defined ring is formed comprising
the person’s contacts and contacts of contacts who may also be
at raised risk of EVD. This second tier of people is of critical
importance to the trial and the public health intervention. The
timing of exposure and intervention means that contacts may
already be incubating the virus at the time of vaccination.
Secondary cases in these individuals may not be averted unless
there is a strong post-exposure prophylactic effect from the
vaccine. However, post-exposure prophylactic effect is not an
objective of the Guinea ring vaccination trial. The trial is instead
premised on immediate vaccination providing rapid pre-exposure
prophylaxis in averting later case generations when compared
with delayed vaccination. This is illustrated in figure 1⇓.
Contacts are defined as individuals who, within the previous
21 days, lived in the same household as the symptomatic patient,
were visited by the symptomatic patient, or were in close
physical contact with the patient’s body or body fluids, linen,
or clothes.8 Contacts of contacts are defined as the neighbours
or extended family members to nearest geographic boundary in
which the local contacts of the index case reside, plus household
members of any high risk contacts who do not live in the same
locality as the case (further details are in the accompanying
protocol). The ring is not necessarily a contiguous geographic
area but captures a social network of individuals and locations
that may include dwellings or workplaces further afield, where
the index patient spent time while symptomatic, or the
households of individuals who had contact with the patient
during the illness or after his or her death.
Before vaccination related activities are initiated, local social
mobilisation experts visit the residents of the main ring site
around the index patient’s residence, seek their consent for the
trial team to approach them, through community leaders and
representatives where applicable, and explain the trial’s
objectives and the implications of potential participation. If
consent is granted for the ring site to be included in the vaccine
trial, a social mobiliser works with trial staff to define the ring,
drawing up a list of all contacts and contacts of contacts in the
ring, regardless of their eligibility for vaccination in the trial.
The process is repeated for satellite sites of the same
epidemiological ring. Randomisation is done by telephone from
the main ring site after the ring is defined and potential
participants determined, stratified by location (urban or rural)
and number of ring members (≤20 or >20). The allocation
sequence was generated by an independent statistician using
randomly varying block lengths and is held on the electronic
data management system with no access for staff involved in
study recruitment.
Once the ring is defined and randomised, informed consent is
obtained from willing and eligible members of the ring.
Allocation is not revealed to participants until after informed
consent. A list is also established of all contacts and contacts
of contacts who are either non-eligible or eligible but not
enrolled in the trial. Reasons for non-enrolment are recorded.
After enrolment, teams visit to administer vaccination as per
the randomised schedule.
An important concern is that the Ebola ça suffit trial must not
detract from patient care or communicable disease control. To
avoid the trial placing additional demands on outbreak control
teams, there are dedicated study field teams which support and
work closely with the Ebola contact tracing and surveillance
teams. Potential cases identified in the course of the study are
assessed by a study physician using a national protocol and
referred to Ebola treatment units for diagnosis and clinical
management as appropriate.
Primary and secondary outcomes
New cases of EVD in the ring are ascertained through active
and passive surveillance using visits to the ring members,
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telephone notification from ring representatives, and case
detection through the national EVD surveillance system.
Contacts are followed up in accordance with usual surveillance
practices. Confirmed cases arising in enrolled ring members
during the relevant ascertainment window are included as
primary outcomes in the main analysis of vaccine efficacy.
Suspected or probable EVD and death from confirmed EVD
are included as secondary outcomes. Confirmed EVD cases in
non-enrolled ring members contribute to secondary analyses of
vaccine effectiveness, including analyses estimating indirect
effects of vaccination, as described in the box and the section
on statistical analysis. Data on serious adverse events will be
collected throughout the trial.
If ring members develop confirmed EVD they are also assessed
as potential new index cases. If at least 60% of the second case’s
contacts and contacts of contacts are outside the first case’s ring
then a second ring that includes all individuals not already
included in the trial is defined and randomised. The 60%
threshold was based on field operational consideration, with the
intention to balance the possible opportunity cost of not
recruiting another distant ring with the evidential gain from
further investigation of a ring around a secondary case.
The box and figure 2⇓ summarise the design and analysis plan
of the trial. Full details of the inclusion and exclusion criteria
and study conduct are in the study protocol (available in
supplementary data on bmj.com). An annotated SPIRIT checklist
is also provided in the supplementary data.9
Ethical and regulatory approvals
Approval to perform the trial was obtained from the Guinean
national ethics committee (Comite National d’Ethique pour la
Recherche en Sante), the Ebola research commission
(Commission Recherche Ébola en Guinée), the WHO Ethical
Research Committee, and the Regional Committees forMedical
and Health Research Ethics (REC) in Norway. Regulatory
approval was obtained from the national medicines regulatory
agency in Guinea (Direction Nationale de la Pharmacie et du
Laboratoire), with regulatory review supported by Health
Canada. The trial is registered with the Pan African Clinical
Trials Registry (PACTR201503001057193).
Statistical analysis of ring vaccination
trials
As vaccination rings can be viewed as clusters and because
randomisation occurs at the level of the ring, the extensive
literature on the design, analysis, and reporting of cluster
randomised trials can be readily adopted.10
The primary analysis in a ring vaccination trial estimates vaccine
efficacy against disease. Vaccine efficacy is defined as VE=1−è,
where è=ë1/ë0 is the hazard ratio of ë1 (the hazard of disease for
eligible and vaccinated individuals in a ring who receive
immediate vaccination) and ë0 (hazard of disease for eligible
individuals in a ring who receive delayed vaccination before
individuals in the ring are vaccinated). To capture events that
can be used for the estimation of vaccine efficacy, the analysis
period is shifted in time. This delay incorporates time for
vaccinated individuals to develop protective immunity and for
disease incubation, as symptom onset times are observed in the
trial rather than the infection times.
The hypothesis test for the primary outcome isH0: VE=0 versus
Ha: VE≠0. The hazard ratio can be estimated using a Cox
proportional hazards regression model. For clustered time to
event data, available methods include random effects models,
also known as frailty models, and stratified proportional hazards
models.11 In the Guinea Ebola ça suffit trial, we will include a
frailty value for each ring.12 If the number of rings is small,
imbalances between the comparison groups are likely to occur
by chance alone. Imbalances in important variables can be
adjusted for in the analysis by incorporating measured
confounders as additional covariates.
To estimate overall vaccine effectiveness, a ring vaccination
trial with delayed vaccination can compare the incidence of
disease between rings randomised to immediate or delayed
vaccination by including events among unvaccinated individuals
in all rings.13 In addition, it is possible to estimate direct
vaccination and indirect vaccination effects. This includes the
degree to which unvaccinated people are protected in rings at
different levels of vaccine coverage.
Study power and sample size
As with any cluster randomised trial, the sample size must be
inflated for the effect of clustering within rings as the members
of a ring share a common exposure to the index case and are
not statistically independent.14 15 The design effect, the amount
by which the sample size must be inflated, depends both on the
degree of correlation within rings (that is, the intraclass
correlation coefficient) and the size of the rings. If the design
effect is high, power will mainly be determined by the number
of rings rather than the total number of individuals enrolled.14 15
If ring size is expected to vary widely, it may be advisable to
further inflate the design effect to account for a potential
reduction in study precision.16
Sample size calculations may be based on the total number of
events that need to be observed to yield a particular level of
power to detect a given vaccine efficacy, or they can be based
on the total number of rings that must be followed, assuming a
particular event rate and ring size. To estimate the design effect
for the trial, it is necessary to assume a particular intraclass
correlation coefficient. Such a value can be approximated from
available pilot data, surveillance records, or the literature.
For the Ebola ça suffit ring vaccination trial, if true vaccine
efficacy is 70%, and intraclass correlation coefficient is 0.05
(based in part on analysis of unpublished data summarising
transmission chains in Guinea, including occurrence of
superspreading events) approximately 190 rings (95 per arm)
of size 50 are required to have 90% power to reject the null
hypothesis. A fixed ring size was used in power calculations as
there was limited data on variability in cluster size in the early
design stages, and the impact of cluster size variability is less
critical than estimated event rate and intraclass correlation
coefficient.
The trial design lends itself naturally to adaptive approaches to
statistical analysis, since estimation and hypothesis testing can
be done as rings accumulate.17 For the Ebola ça suffit trial,
interim analysis will be performed using an alpha spending
strategy with truncated O’Brien-Fleming boundaries and a first
review likely around 100 rings.18 Interim analysis will allow the
trial to be stopped early if there is compelling evidence of
vaccine efficacy, which may allow the vaccine to be more
quickly deployed outside of a study.
Discussion
The Ebola ça suffit ring vaccination trial design proposed here
was developed in response to the urgent need to evaluate
experimental vaccines against Ebola virus disease (EVD) and
began in April 2015.
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Synopsis of Ebola ça suffit randomised controlled trial: a ring vaccination trial to evaluate the safety and efficacy
of an Ebola vaccine in Guinea, West Africa (PACTR201503001057193)
Setting
Basse Guinea, the area of the country where most of the EVD cases are being reported by March 2015. It includes five prefectures: Conakry,
Coyah, Kindia, Forécariah, Dubreka.
Primary objective
To assess vaccine efficacy against confirmed Ebola virus disease (EVD) by performing a clinical trial comparing immediate versus delayed
ring vaccination.
Secondary objectives
• To assess vaccine effectiveness (indirect and overall) in preventing confirmed EVD, using both direct calculation and transmission
dynamic modelling
• To assess vaccine efficacy against death from confirmed EVD
• To assess vaccine efficacy against probable and suspected EVD
• To evaluate vaccine safety by assessing serious adverse events.
Randomised comparison
Immediate vaccination of rings with a single dose is compared with delayed vaccination of rings with single dose, with a delay of 21 days.
Definition of rings and inclusion criteria
Laboratory confirmed EVD cases trigger visits for ring definition. Based on contact tracing and places of residence of the case, an
epidemiologically defined sociogeographical ring is identified. Individuals aged ≥18 years (excluding pregnant or breastfeeding women and
others meeting exclusion criteria) who live in the defined vaccination ring are offered vaccination.
Outcomes
Confirmed EVD is the primary outcome. Secondary outcomes include suspected and probable cases and serious adverse events (seeWHO
details of contact tracing during an EVD outbreak8 for case definitions).
Study assessments and follow-up
The study team enumerates the residents of the ring, seeks their informed consent, assesses eligibility, and vaccinates them if they are
willing and eligible. Follow-up visits are conducted at days 3, 14, 21, 42, 63, and 84 after vaccination. The study team inquires about any
symptoms or signs to ascertain the occurrence of serious adverse events or EVD and any other changes in health status of volunteers since
previous visit.
Sample size
Approximately 190 rings (95 per arm) of size 50 are required to have 90% power to reject the null hypothesis. The final sample size achieved
will depend on the number of new index cases accumulating during the study period. Interim analysis is planned using an alpha spending
strategy that may allow the trial to conclude early if compelling evidence of a significant protective vaccine effect is observed (see main text).
Risk of bias
Random allocation of vaccination rings is done remotely, by a member of the study team not involved in the definition of rings. The study is
open label, so blinding of participants and field teams is not possible. Informed consent and eligibility are done after randomisation of each
ring, with participants advised of their allocation after informed consent. Communicable disease control measures other than ring vaccination
are identical in the two groups.
The ring vaccination trial design combines approaches from
clinical trial methodology, infectious disease epidemiology, and
applied public health into a pragmatically informed efficacy
and effectiveness trial that can be implemented in a
resource-poor country during an epidemic. The design allows
evaluation of the efficacy of the vaccine at the individual level
and of the effectiveness of ring vaccination as a containment
strategy. A ring vaccination trial therefore both implements and
evaluates a public health intervention.
A practical advantage of the ring vaccination trial design is that
all eligible participants within the ring can be vaccinated and
followed up around the same time in the same location, at their
place of residence. In addition, the design is less affected by
low incidence than a standard parallel group design, as it is
always being conducted in small pockets of high risk individuals.
Variations on this trial design may thus in future be used to
evaluate vaccines against rare diseases, such as meningococcal
disease, or to evaluate vaccines that become available towards
the end of an outbreak. Indeed ring vaccination trials need not
be limited to vaccines but could evaluate, for example, group
health education or chemoprophylaxis given in response to
infectious disease cases.
Because of extensive field operational challenges—including
community resistance, difficulty reaching remote field sites,
and vaccine transportation at −80°C—the Ebola ça suffit trial
forgoes two of the routine practices of randomised controlled
trials. The first is that there are no placebo vaccination visits
for double blinding. To reduce the risk of bias arising from
behaviour changes that might follow vaccination, participants
are informed that it is not known if the vaccine works and that
they must still take steps to avoid infection. The second is that
rings are randomly allocated before individual informed consent
is obtained. Although the consent team are aware of allocation,
making this de facto unconcealed, participants are told of their
vaccination schedule only at the end of the informed consent
process. Monitoring of recruitment to date has not indicated
differences between study arms, though selection bias cannot
be excluded.
The ring vaccination trial design shares the limitations of cluster
randomised controlled trials.14 19 The need to increase sample
size due to cluster randomisation can, however, be balanced by
the substantially higher event rate in ring vaccination trial
participants compared with an individually randomised trial in
the general population of an affected area, which may result in
a smaller overall sample size. The biases that are particularly
relevant to cluster randomised controlled trials also apply to
ring vaccination trials, including imbalances in important
variables at the level of the ring.19 The Ebola ça suffit trial
initiates new rings linked to secondary cases in study rings in
order to maximise the number of rings recruited; this omits
buffer zones used to reduce inter-cluster contamination.15
Potential confounding variables—including participation rates,
index case characteristics such as days to isolation, and
comparability of rings, ring populations, and drop-out rates—can
be measured and adjusted for. Intensive follow-up regimens
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and use of national case surveillance can reduce the likelihood
of differential ascertainment of endpoints.
A ring vaccination trial using delayed vaccination as the control
arm addresses one of the ethical concerns of placebo controlled
trials, which are seen to arbitrarily deny some participants access
to potentially effective interventions.7 Such a design is more
complex to analyse than a placebo controlled study. Crucially,
it is important to clarify the equivalent time periods for which
the comparison is made. The Ebola ça suffit trial’s primary
analysis uses a fixed delay to account for the incubation period
and the time for development of immunity after vaccination,
both of which are expected to vary across individuals. The
impact will be some misclassification of trial events resulting
in an estimate of vaccine efficacy that is biased towards the null.
Further details are described in the statistical analysis plan and
a forthcoming publication.
As noted, a ring vaccination trial tests both the vaccine and the
vaccination strategy. It is possible that in a ring vaccination
trial, an efficacious vaccine may not be shown to be so, either
because the ring vaccination delivery strategy or the ring
vaccination trial design is unsuitable for the vaccine. This may
be due to the concurrent non-vaccine control measures, or to
issues with the timing of vaccine delivery and immunity onset
relative to exposure.
In conclusion, we propose a novel design to estimate efficacy
and effectiveness of experimental vaccines during outbreaks,
and have implemented this design to test a vaccine against EVD
in Guinea. Although the number of new EVD cases has declined
in Guinea in recent months, it is possible that the epidemic will
continue for some time at a lower intensity. We hope that the
vaccine tested in the Ebola ça suffit trial will contribute to
ending the epidemic. Should efficacy not be demonstrated in
the current outbreak, the adaptive nature of the ring vaccination
trial design would make it plausible to issue a preliminary report
after cessation of transmission and to reactivate or initiate a
modified version of the trial when the next Ebola zoonotic
transmission event occurs.20
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Figures
Fig 1 Development of cases arising in two hypothetical, simplified, example trial rings, which are identical but for receipt of
immediate or delayed (by 21 days) vaccination. Case boxes indicate the presence of symptoms and infectiousness. Arrows
indicate disease incubation periods after infection. Because disease onset is detected rather than the point of infection, the
shaded areas show periods in which any cases arising would be excluded from an analysis of vaccine efficacy against
infection. This example shows a window which assesses the vaccine’s ability to offer protection from the day of administration.
Three cases arise during the trial; one contributes to the analysis
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Fig 2 Schematic presentation of the design of a ring vaccination trial during an outbreak of an infectious disease
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